{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-22-000041","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.474707+00:00","generated_at":"2026-06-22T00:33:14.860087+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lexicon Q3 net loss $23.4M; sotagliflozin NDA on track for May 2023; cash $136.2M","bullets":["Net loss of $23.4M ($0.13 per share) vs $23.1M ($0.16) in Q3 2021.","Cash and investments $136.2M at Sep 30, 2022, up from $86.7M at Dec 31, 2021 after $94.3M net proceeds from public offering and private placement.","NDA for sotagliflozin in heart failure accepted, PDUFA target action date May 2023; mid-cycle review meeting completed.","Final data from RELIEF-DPN-1 (LX9211) in painful diabetic neuropathy to be presented; enrollment complete in RELIEF-PHN-1 study with top-line data expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-22-000041","json":"https://secwatch.observer/filing/0001062822-22-000041.json","markdown":"https://secwatch.observer/filing/0001062822-22-000041.md","text":"https://secwatch.observer/filing/0001062822-22-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282222000041/0001062822-22-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282222000041/lxrx-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:33:14.860087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4aff6c93e1327d83d25ed7477726253249593eb","claim":"LEXICON PHARMACEUTICALS, INC. reported the three months ended September 30, 2022 results: net income $23.4 million, or $0.13 per share.","evidence_excerpt":"Net loss for the third quarter of 2022 was $23.4 million, or $0.13 per share, as compared to a net loss of $23.1 million, or $0.16 per share, in the corresponding period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282222000041/0001062822-22-000041-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"$23.4 million, or $0.13 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}